Cumberland Partners Ltd Has $36.67 Million Stock Position in Eli Lilly and Company $LLY

Key Points

• Cumberland Partners Ltd increased its Eli Lilly stake by 7.1% in the fourth quarter, ending with 34,125 shares valued at about $36.67 million. Eli Lilly is now its 15th-largest holding, representing 2.2% of its portfolio.
• Eli Lilly reported strong quarterly results, with EPS of $8.55 beating estimates and revenue rising 55.5% year over year to $19.8 billion. The company also issued FY 2026 guidance of 35.5 to 37.0 EPS.
• Analysts remain broadly positive on the stock, with multiple firms raising price targets and the consensus rating staying at Moderate Buy. Recent headlines also highlight optimism around Lilly’s pipeline, including obesity, Alzheimer’s, and heart-failure developments.

Cumberland Partners Ltd lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,125 shares of the company's stock after purchasing an additional 2,250 shares during the quarter. Eli Lilly and Company accounts for 2.2% of Cumberland Partners Ltd's holdings, making the stock its 15th biggest holding. Cumberland Partners Ltd's holdings in Eli Lilly and Company were worth $36,673,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of LLY. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares in the last quarter. 10Elms LLP grew its holdings in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 10 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $33,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,066.59 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.00 trillion, a PE ratio of 37.89, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock's 50-day simple moving average is $942.87 and its 200 day simple moving average is $1,003.77.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the firm posted $3.34 earnings per share. The business's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Guggenheim reaffirmed a "buy" rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 2nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. HSBC lowered Eli Lilly and Company from a "hold" rating to a "reduce" rating and reduced their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, Jefferies Financial Group raised their price objective on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,220.37.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.